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ABSTRACT
Livin/BIRC7 is a member of the inhibitors of apoptosis proteins family, which 
are involved in tumor development through the inhibition of caspases. Aim was to 
investigate the expression of livin and other members of its pathway in adrenocortical 
tumors and in the adrenocortical carcinoma (ACC) cell line NCI-H295R. 
The mRNA expression of livin, its isoforms α and β, XIAP, CASP3 and DIABLO 
was evaluated by qRT-PCR in 82 fresh-frozen adrenal tissues (34 ACC, 25 adenomas 
= ACA, 23 normal adrenal glands = NAG). Livin protein expression was assessed by 
immunohistochemistry in 270 paraffin-embedded tissues (192 ACC, 58 ACA, 20 NAG). 
Livin, CASP3 and cleaved caspase-3 were evaluated in NCI-H295R after induction of 
livin overexpression.
Relative livin mRNA expression was significantly higher in ACC than in ACA and 
NAG (0.060 ± 0.116 vs 0.004 ± 0.014 and 0.002 ± 0.009, respectively, p < 0.01), being 
consistently higher in tumors than in adjacent NAG and isoform β more expressed than α.  
No significant differences in CASP3, XIAP and DIABLO levels were found among these 
groups. In immunohistochemistry, livin was localized in both cytoplasm and nuclei. 
The ratio between cytoplasmic and nuclear staining was significantly higher in ACC 
(1.51 ± 0.66) than in ACA (0.80 ± 0.35) and NAG (0.88 ± 0.27; p < 0.0001). No 
significant correlations were observed between livin expression and histopathological 
parameters or clinical outcome. In NCI-H295R cells, the livin overexpression slightly 
reduced the activation of CASP3, but did not correlate with cell viability.
In conclusion, livin is specifically over-expressed in ACC, suggesting that it might 
be involved in adrenocortical tumorigenesis and represent a new molecular marker 
of malignancy.
INTRODUCTION
Adrenocortical tumors (ACT) consist in frequent 
adenomas (ACA) and rare highly malignant carcinomas 
(ACC). ACC is one of the most aggressive solid tumors in 
humans, as evidenced by a 5-year survival rate of 25–50% 
in most series [1–3]. Effective treatment options for 
patients with advanced ACC are still scant. Thus, malignant 
adrenocortical tumors remain a major therapeutic challenge 
and new targets for treatment are urgently needed [4]. In 
addition, the histopathological diagnosis of ACC is usually 
based on multiple morphologic parameters, like the widely 
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used Weiss diagnostic score [5], that are suggestive, but not 
always pathognomonic of malignancy [6]. Thus, although 
most adrenal tumors are not diagnostic dilemmas, there 
are still cases that are challenging [7] and novel molecular 
markers potentially leading to distinguish benign from 
malignant tumors are still needed.
The inhibitor of apoptosis proteins (IAP) family 
plays a key role in the regulation of apoptosis, cell 
proliferation and cell cycle control, mostly through the 
direct inhibition of specific caspases [8]. Currently, eight 
humans IAPs have been identified, including neuronal IAP 
(NAIP/BIRC1), cellular IAP1 (cIAP1/BIRC2), cellular 
IAP2 (cIAP2/BIRC3), X linked IAP (XIAP/BIRC4), 
survivin (BIRC5), BIR-containing ubiquitinin-conjugating 
enzyme (Bruce/Apollon/BIRC6), melanoma-IAP (ML-
IAP/livin/BIRC7) and IAP-like protein 2 (ILP2/BIRC8). 
These proteins contain at least one of a highly conserved 
zinc-binding domain called BIR (baculovirus IAP repeat) 
motif, which is involved in protein-protein interaction and 
inhibition of caspases [9].
Livin/BIRC7 was first identified in melanoma [10] 
and consists of a single BIR domain that is homologous 
to the BIR3 domain of others IAPs [11], and a RING 
(Really Interesting New Gene) Zink finger domain. The 
gene BIRC7 encodes two splicing variants: livin α and 
livin β, which are almost identical, except for 18 amino 
acids located in the BIR-RING interlinking region present 
only in the α isoform [12]. Despite this high similarity, the 
two isoforms are involved in the anti-apoptotic response 
to different stimuli. For example, livin α was associated 
with resistance against staurosporine while livin β was 
associated with resistance to etoposide, UV irradiation and 
TNF-α induced apoptosis [12, 13]. 
Livin exerts its anti-apoptotic effect especially 
through inhibition of caspase 3, but also of caspases 7 and 
9 and of Smac/DIABLO (second mitochondria-derived 
activator of caspase/direct IAP binding protein with low p). 
Livin, binding DIABLO through its BIR domain, prevents 
also DIABLO–XIAP interaction, thus XIAP is also free 
to inhibit caspases. DIABLO is the major antagonist of 
IAP proteins [9], sensitizes tumor cells to apoptosis and 
controls the tumor growth and/or its metastatic spread [14]. 
This pro-apoptotic function has prompted the synthesis 
of Smac mimetics (peptides, polynucleotides and 
compounds) that target the BIR domain of IAPs and could 
be used in cancer therapy to either specifically induce 
apoptosis or act as drug-sensitizers [15, 16]. Such Smac 
mimetics, like the monovalent compounds GDC-0152 
and GDC-0917 (CUDC-427) and the bivalent compound 
TL32711 (Birinapant) are being investigated in more than 
twenty phase I and II clinical trials in solid cancers and 
hematologic tumors (ClinicalTrials.gov). 
Livin is highly expressed in fetal tissue and placenta 
[12] and in several tumor types, such as renal cell, bladder 
and colon cancer [17–19], hepatocellular carcinoma [20], 
non-small cell lung cancer [21], neuroblastoma [22] and 
childhood lymphoblastic leukemia [23]. Livin up-regulation 
is mainly a risk factor for cancer progression, poor prognosis 
and resistance to anti-tumor treatment [24, 25]. However, 
in some tumors, such as in childhood acute lymphoblastic 
leukemia, malignant mesothelioma, renal cell carcinoma and 
hepatocellular carcinoma, high livin expression is correlated 
with better prognosis [23, 26–28] or has no impact on 
clinical outcome [20, 29]. Furthermore, several studies 
demonstrated a negative correlation between the expression 
of livin and caspase-3 [24, 30, 31], which represents the 
main molecular target of livin action. Moreover, it has been 
shown that down-regulation of livin expression resensitizes 
tumor cells to apoptosis and chemotherapy [13, 25, 32] and 
leads to tumor volume reduction in a xenograft model of 
colorectal cancer [33]. For all these reasons, livin might 
represent a new potential target for future tumor-specific 
therapeutic strategy [9, 15, 34]. 
In a previous study on genomic alterations in 
adrenocortical tumors, we identified recurrent copy number 
gains at the region 20q13.3 (including the gene BIRC7) 
in 6/24 ACA (25%) and in 14/22 ACC (68%). Looking 
at other genes involved in the pathway of BIRC7, we 
found frequent copy number gains also in chromosomal 
region 12q (including DIABLO) in 11/22 ACC (50%) [35]. 
We previously demonstrated that survivin/BIRC5 has a 
higher expression in adrenocortical tumors than in normal 
adrenal glands and that its expression correlates with 
prognosis in ACC group [36]. Several studies indicated that 
livin and survivin play together an important role in the 
tumorigenesis and in the clinical outcome of several human 
cancers [18, 37]. The expression of other components of 
IAP family has been poorly evaluated in adrenocortical 
tissues [22]. 
The aim of the study was a comprehensive 
evaluation of livin/BIRC7 expression and its pathway 
in normal and neoplastic adrenal tissues, as well as 
in different adrenocortical cell lines, and its potential 
involvement in adrenocortical tumorigenesis. Moreover, 
we utilized the ACC reference cell line, NCI-H295R, 
to investigate in vitro the biological role of livin in the 
adrenocortical cell system.
RESULTS
Livin, isoforms α and β, CASP3, DIABLO and 
XIAP mRNA expression in adrenocortical tissues
Relative livin mRNA expression was significantly 
higher in ACC (0.060 ± 0.116) than in both ACA and normal 
adrenal gland (NAG) (0.004 ± 0.014 and 0.002 ± 0.009, 
respectively, p < 0.005) (Figure 1A). There was no 
difference between NAG coming from adrenalectomies 
due to kidney cancer (n = 3, mean: 0.0002 ± 0.0001) and 
NAG adjacent to an adrenocortical tumor (n = 20, mean: 
0.0026 ± 0.009, p = n.s.). Accordingly, when we analyzed 
the paired tumor/adjacent normal adrenal samples, livin was 
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consistently higher in tumors (in both ACC and ACA) than 
in adjacent adrenal tissues (0.101 ± 0.131 vs 0.008 ± 0.016 
and 0.001 ± 0.002 vs 0.0003 ± 0.0018 in ACC and ACA 
vs adjacent NAG, respectively; Figure 1B and 1C). Similar 
results were observed for livin isoforms α and β, which 
were both more expressed in ACC (0.019 ± 0.037 and 
0.068 ± 0.121, respectively) than ACA (0.008 ± 0.036, 
p = 0.005 for livin α and 0.020 ± 0.084, p = 0.001 for 
livin β) and NAG (0.001 ± 0.004, p < 0.001 for livin α and 
0.004 ± 0.012, p < 0.001 for livin β). 
The relative CASP3 mRNA levels were 
significantly higher in ACA (0.024 ± 0.012) than in ACC 
(0.017 ± 0.011, p = 0.03) and NAG (0.018 ± 0.012, 
p = 0.05). Instead, XIAP was significantly higher in NAG 
(0.033 ± 0.020) than ACC (0.022 ± 0.018, p < 0.05); 
no differences were found with ACA (0.028 ± 0.023). 
DIABLO mRNA levels were similar between NAG 
(0.245 ± 0.179) and adrenocortical tumors (0.241 ± 0.204 
and 0.232 ± 0.189, respectively in ACC and ACA). For 
all these genes, we did not find any difference between 
paired samples of tumors and adjacent adrenal glands as 
we observed for livin. 
Concerning the relationship with clinical 
parameters, we observed a significant inverse correlation 
between CASP3 expression and tumor size (p = 0.005, 
R = 0.36). No other significant correlations were observed 
between the mRNA expression of investigated genes and 
clinical or pathological parameters including hormone 
secretion pattern, ENSAT tumor stage, Weiss score and 
Ki67 proliferation index. Moreover, no significant impact 
on progression-free and overall survival was found for all 
investigated genes (Supplementary Table S1). 
Livin α and livin β in adrenocortical tumors and 
adjacent normal adrenal glands
To better investigate the expression of livin isoforms 
in adrenal tissues, we compared livin α and livin β 
expression at mRNA level by RT-PCR (size differentiation 
agarose gel electrophoresis) (Figure 2A–2B) and protein 
level by Western Blot (WB) analysis (Figure 2C–2D) 
in 15 paired samples of adrenocortical tumors (10 ACA 
and 5 ACC) and adjacent adrenal glands. Both livin α 
and β were detected in all the 15 normal and neoplastic 
adrenocortical tissues with isoform β having generally a 
higher expression than the isoform α (Figure 2A and 2C). 
At mRNA level, isoform α was significantly higher 
in tumors than in corresponding NAG (p = 0.003), while 
isoform β showed only a trend (p = 0.07) (Figure 2B). At 
protein level, livin β was significantly higher in tumors 
than in corresponding NAG (p = 0.004) and was significant 
higher than isoform α in both tumors (p < 0.0001) and 
NAG (p < 0.0001) (Figure 2D). No difference was 
observed for livin α protein expression between ACT and 
adjacent NAG (Figure 2D). 
Livin α and livin β in adrenocortical cancer cell 
lines
The relative livin mRNA expression was relatively 
low in all the ACC cell lines NCI-H295, NCI-H295R and 
SW13 compared to positive controls (Supplementary 
Figure S1A). The isoform β was higher expressed than 
the isoform α (Supplementary Figure S1B), similarly to 
what we reported for the adrenocortical tumors. The WB 
Figure 1: Relative livin mRNA expression levels by quantitative real time RT-PCR analysis. Relative livin mRNA expression 
levels in normal adrenal glands (NAG), adrenocortical adenoma (ACA) and adrenocortical carcinoma (ACC) in the entire cohort of patients, 
expressed in log scale (A) and in 19 paired samples of tumor and corresponding NAG, of which 6 ACC (B) and 13 ACA (C) (p < 0.005 per 
trend). Statistical analysis by Kruskall-Wallis test. N.s.= p not significant.  
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analysis showed moderate, but relatively low, livin protein 
expression levels in NCI-H295R cells (Supplementary 
Figure S1C).
Immunohistochemical evaluation of livin protein 
expression 
As expected, livin cytoplasmic staining was higher 
in tumors than in adjacent normal tissue in all studied 
samples, including skin (Supplementary Figure S2A), 
kidney (Supplementary Figure S2B), adrenal gland 
(Figure 3A1–3A4), colon and testis. Renal cell carcinoma 
and melanoma lymph node metastasis showed the 
strongest staining intensity (H-score 3). Livin staining 
was detected also in some specific cells of normal tissues, 
such as glomerular mesangial cells, podocytes and 
tubule epithelial cells in normal kidney (Supplementary 
Figure S2B. S2a–b), crypt epithelial cells in normal colon, 
gastric glands in normal stomach and seminiferous tubules 
in normal testis. Similarly, we observed a positive livin 
immunostaining also in hormone-secreting cells of the 
cortex and the medulla of the normal adrenal gland, but 
not in the stroma and in the capsular tissue (Figure 3A1–2 
and Figure 4). Specifically, the zona glomerulosa and 
fasciculata (Figure 4A1–2) showed a cytoplasmic staining 
(both mean H-score: 1.60 ± 0.89) and positive nuclei in 
less than 50% of cells (mean nuclear score: 0.80 ± 0.84 
and 1.20 ± 0.84, respectively), while the zona reticularis 
showed the highest staining in both cytoplasm (mean 
H-score: 2.20 ± 0.84) and nuclei (mean nuclear score: 
1.60 ± 0.55) (Figure 4A3). The medulla presented higher 
immunostaining than adrenal cortex, both at cytoplasm 
(mean H-score: 2.70 ± 0.58) and nuclear level (mean 
nuclear score: 1.60 ± 0.55). 
Moreover, livin cytoplasmic immunostaining was 
significantly higher in ACC (mean H-score: 2.00 ± 0.61) 
than in both ACA (1.67 ± 0.57) and NAG (1.45 ± 0.69, 
p = 0.01 per trend by Kruskall-Wallis test) (Figure 5A). 
However, no significant difference was found between the 
ACC and ACA group. In the ACC group, no difference 
in livin expression was observed among primary tumors, 
local recurrences and metastatic tissues (data not shown). 
Figure 2: Expression of livin isoforms α and β in adrenocortical tumors and adjacent normal adrenal glands. 
(A) 4× agarose gel for the expression of livin isoforms α and β at mRNA analyzed by RT-PCR in a subgroup of 4 paired samples of tumors 
(2 adrenocortical adenomas = ACA, and 2 adrenocortical carcinomas = ACC) and adjacent normal = NAG. Hela cells were used as positive 
control and β2-microglobulin was used as internal standard. (B) Quantitative analysis of agarose gel bands of all 15 paired samples of 
adrenocortical tumors (ACT) and corresponding NAG (p = 0.3 per trend). Each bar in the histograms represents the mean of the ratio livin α 
or livin β signal to β2-microglobulin signal. (C) Western blot analysis of livin isoforms expression in three of four paired samples of tumors 
(2 ACA and 1 ACC) and adjacent NAG that are showed also at mRNA levels. Whole cell lysate SK-MEL 28 was used as positive control 
and β-actin was used as internal standard. (D) Quantitative analysis of WB bands of all 15 paired samples of tumors and corresponding 
NAG (p < 0.0001 per trend). Each bar in the histograms represents the mean of the ratio livin α or livin β signal to β-actin signal. Statistical 
analysis by Kruskall-Wallis test and Mann-Whitney U test. N.s. = p not significant.  
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Contrary to the cytoplasmic staining, livin nuclear 
staining was clearly higher in ACA (Figure 3C1–2) (mean 
nuclear score: 2.28 ± 0.72) than in ACC (1.34 ± 0.57) 
(Figure 3B1–2), and NAG (1.70 ± 0.66) (p < 0.0001 per 
trend by Kruskall-Wallis test). Interestingly, we observed 
that the ratio between cytoplasmic and nuclear staining 
was significantly higher in ACC (mean ratio: 1.51 ± 0.66) 
than in ACA (mean ratio: 0.80 ± 0.35) and NAG (mean 
ratio: 0.88 ± 0.27) (p < 0.0001 per trend by Kruskall-
Wallis test), while no significant difference was found 
between ACA and NAG (Figure 5B). 
We did not observe any significant correlations 
between both cytoplasmic and cytoplasmic/nuclear ratio 
protein level and clinical or pathological parameters, 
including hormone secretion pattern, ENSAT tumor stage, 
Weiss score, Ki67 proliferation index, and number of 
distant metastasis. No correlations were observed between 
livin isoforms α and β at mRNA level and cytoplasmic 
or nuclear staining. No impact on clinical outcome was 
found for both cytoplasmic and cytoplasmic/nuclear ratio 
staining (Supplementary Figure S3A–S3D).
In a total of 31 adrenocortical tumors (10 ACA and 
21 ACC) we evaluated the livin expression at both mRNA 
and protein level, observing a strong positive correlation 
(Supplementary Figure S4). In particular, cytoplasmic livin 
protein staining was higher in ACT showing high livin 
mRNA levels (n = 16, of which 14 with H-score 2–3) as 
compared with ACT with low mRNA levels (n = 15, of 
which 9 with H-score 2–3, p < 0.0001 by Chi-squared test).
Relationship between livin cytoplasmic staining 
and copy number gains
A total of 32 adrenocortical tumors (17 ACA and 
15 ACC) were evaluated in a previous study by single 
nucleotide polymorphism (SNP) array analysis profiling 
[35]. In this group, we observed a recurrent copy number 
(CN) gain at the region 20q13.3 including the gene BIRC7 
Figure 3: Hematoxylin & eosin and livin staining in adrenal samples. (A) Normal adrenal gland (NAG) (A.1–2) with adjacent 
adrenocortical carcinoma (ACC) (A 3-4) stained for H&E (A.1 and A.3) and livin (A.2 and A.4). A.1b, 2b and A.3b, 4b are 10× enlarged 
and detailed images of the 2× NAG and ACC, respectively. Arrows point to tumor infiltration in the adjacent NAG. TC: capsule, separating 
NAG and ACC. (B) Example of ACC with H-score 3 and negative nuclei stained for H&E (B.1) and livin (B.2) in comparison with 
(C) adrenocortical adenoma (ACA) characterized by H-score 2 and positive nuclei stained for H&E (C.1) and livin (C.2). The figures B.1b, 
2b and C.1b, C.1c are 20× enlarged and detailed images of the 10× ACC and ACA, respectively. Scale bar: 100 µm.
Oncotarget9328www.impactjournals.com/oncotarget
in 6 ACA and 8 ACC. Overlapping the expression data on 
the CN data, we observed a trend to a positive correlation 
between CN status and cytoplasmic livin protein 
expression. Specifically, the staining was higher, even if 
not significantly, in ACT affected by CN gain (n = 14, of 
which 12 with H-score 2–3) as compared with ACT with 
normal CN status (n = 18, of which 11 with H-score 2–3, 
p = 0.234 by Chi-squared test with absolute values). 
Relationship between cytoplasmic localization of 
livin and survivin stainings 
In a subgroup of 146 adrenal samples, we observed 
a strong relationship between the cytoplasmic livin and 
survivin staining (p = 0.0123 calculated by Chi-squared 
test) (Supplementary Figure S5). Specifically, survivin 
expression was low (H-score 0–1) in 31 tissue samples 
(including 24 ACC, 4 ACA and 3 NAG), of which 14 
samples also had low cytoplasmic livin, whereas survivin 
was high (H-score 2–3) in 115 tissue samples (comprising 
94 ACC, 16 ACA and 5 NAG), of which 95 cases had also 
high livin cytoplasmic. 
In a subgroup of 93 ACC cases deriving from 
primary tumors, we evaluated the impact of the two 
proteins on clinical outcome. However, we did not observe 
any significant impact on overall and progression free 
survival by combining the expression of the two proteins 
(data not shown).
Figure 4: Livin staining in normal adrenal gland. Livin staining in normal adrenal gland (A). It is possible to recognize the three 
different zone of the adrenal gland: the zona glomerulosa (ZG), the zona fasciculata (ZF) and the zona reticularis (ZR). The Figures (B) and 
(C) are 20× enlarged and detailed images of the 10× ZG, ZF and ZR, respectively. Scale bar: 100 µm.
Figure 5: Immunohistochemistry of cytoplasmic livin expression and cytoplasmatic/nuclear ratio in adrenocortical 
tissues. (A) Livin cytoplasmic protein expression evaluated as H-score in normal adrenal glands (NAG, n = 20), adrenocortical adenomas 
(ACA, n = 58) and adrenocortical carcinomas (ACC, n = 192) (p = 0.01 per trend). (B) Livin cytoplasm/nuclear protein expression ratio 
evaluated as the ratio between H-score and nuclear score in NAG (n = 20), ACA (n = 58) and ACC (n = 192) (p < 0.0001 per trend). 
Statistical analysis by Kruskall-Wallis test. N.s. = p not significant.
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Effect of livin overexpression on adrenocortical 
cells in vitro 
Livin overexpression was successfully induced in 
NCI-H295R cells (livin-NCI-H295R) (Figure 6A, 6C and 
6E). Accordingly, after 48 and 72 hours from transfection, 
the livin α and livin β mRNA and protein levels were 
increased in livin-NCI-H295R cells in respect to those 
transfected with the empty vector (pCMV6-NCI-H295R; 
Figure 6A and 6C). Particularly, after 72 hours from 
transfection, livin isoforms were significantly increased 
at both mRNA (23.32 ± 8.86 vs 0.000013 ± 0.000005, 
p = 0.04 and 18.42 ± 5.28 vs 0.000070 ± 0.000042, 
p = 0.02 for livin α and livin β, respectively, by unpaired 
t-test with Welch’s correction, Figure 6A) and protein 
levels (2.75 ± 0.59 vs 0.06 ± 0.06, p = 0.028 and 
2.30 ± 0.75 vs 0.01 ± 0.01,  p = 0.008 for livin α and livin β, 
respectively, by unpaired t-test with Welch’s correction, 
Figure 6C–6D) in livin-NCI-H295R cells in comparison 
to control pCMV6-NCI-H295R cells. 
To determine the impact of livin overexpression 
on apoptosis, we evaluated CASP3 expression at mRNA 
level by qRT-PCR and cleaved caspase-3, the active 
form of this enzyme, at protein level by both WB and 
immunofluorescence (IF). We observed that CASP3 
mRNA levels significantly decrease in livin-NCI-H295R in 
comparison with pCMV6-NCI-H295R cells after 72 hours 
from transfection (0.0055 ± 0.0005 vs 0.0093 ± 0.0011, 
p = 0.015 by unpaired t-test with Welch’s correction; 
Figure 6B). At WB analysis (Figure 6C–6D), the cleaved 
caspase-3 was partially decreased in livin-NCI-H295R in 
comparison to pCMV6-NCI-H295R cells both at 48 and 
72 hours after transfection (2.09 ± 1.09 vs 2.48 ± 0.81, 
p = n.s. at 72 hours by unpaired t-test with Welch’s 
correction; Figure 6D). IF staining after 72 hours from 
transfection, revealed in the evaluated cells a significant 
reduction of cleaved caspase-3 in the livin-NCI-H295R 
cells (mean percent of cleaved caspase-3 positive cells: 
10.76 ± 6.41 vs 23.84 ± 11.51, p = 0.003 for livin-NCI-
H295R and pCMV6-NCI-H295R  cells, respectively, by 
unpaired t-test with Welch’s correction; Figure 6E). 
A cell viability test was performed at 48 and 72 hours 
after transfection to assess the direct potential role of livin 
on cell proliferation. Importantly and according with the 
results of the immunostaining in tissue samples, we did 
not find any significant difference between the livin-NCI-
H295R and pCMV6-NCI-H295R (data not shown). 
DISCUSSION
Livin/ML-IAP/BIRC7 is a member of the inhibitor 
of apoptosis proteins family, which plays a key role in 
the regulation of apoptosis and modulation of cell cycle 
and cell proliferation. Livin is over-expressed in several 
cancer types and presents an anti-apoptotic activity 
mediated mostly by the direct inhibition of caspase 3, but 
also of caspases 7 and 9 and DIABLO. To our knowledge, 
this is the first study that systematically investigates 
the expression of livin/BIRC7 and different members 
of its pathway in normal and neoplastic adrenocortical 
tumors. In particular, we could demonstrate that livin 
is more expressed in ACC than in ACA and NAG, both 
at mRNA and protein level. These results are conform 
to gene expression data extracted from the high density 
oligonucleotide array of adrenocortical tumors published 
by Giordano and colleagues [38] and deposited in 
National Center for Biotechnology Information´s gene 
Expression Omnibus (accession number GSE10927) 
which showed that livin is significantly higher expressed 
in ACC in comparison to ACA and normal adrenal glands 
(Supplementary Figure S6). Similarly, in a very recent 
multicentric study regarding a comprehensive genomic 
characterization of a large series of 80 ACC [39], the 
authors found a relatively high livin mRNA expression 
by RNA-sequencing (median log fold change = 5.96). All 
these findings suggest a potential major role of livin in the 
adrenocortical tumor development, as previously reported 
for other cancer types [18–20, 29, 40–42]. 
Interestingly, we also observed a significant positive 
correlation between the livin mRNA expression and 
protein levels as evaluated by immunohistochemistry, in 
contrast to what was previously reported by Lazar et al. in 
melanoma [43]. As demonstrated in renal cell carcinoma, 
in hepatocellular carcinoma and colorectal cancer 
[19, 20, 40], we were able to show that livin is upregulated 
in tumor tissues compared to the adjacent normal adrenal 
gland, again both at mRNA and protein level. In contrast 
to Kim and colleagues [22], we detected livin staining in 
hormone-secreting cells of normal adrenal glands, not only 
in medulla but also in the adrenal cortex. 
BIRC7 gene encodes two splicing variants, livin 
α and livin β, known to have different anti-apoptotic 
properties in vitro [12, 13] and also a different expression 
in tissues. Particularly, livin β seems to be more effective 
than the α isoform in blocking apoptosis induced by DNA 
damaging agents such as etoposide [12]. We observed 
that adrenocortical tumors and normal adrenal glands 
expressed both livin α and β isoforms, at both mRNA 
and protein level. This is in agreement with studies 
performed in renal cell carcinoma and in hepatocellular 
carcinoma [20, 40] and in contrast to bladder cancer, 
where only the α subunit is expressed [18]. Furthermore, 
we demonstrated that livin β is more expressed than the α 
isoform in both adrenocortical tumors and normal adrenal 
glands. However, we did not observe any significant 
correlation between the two isoforms and the clinical and 
pathological features. Further studies are needed to better 
elucidate the pathological role of the two livin isoforms in 
adrenocortical tumors.
We did not found any significant correlation between 
livin expression at both mRNA and protein  levels, and the 
histopathological and/or clinical parameters, including the 
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Figure 6: Effect of livin overexpression on adrenocortical cell line NCI-H295R in vitro. Relative livin mRNA levels (A) and 
CASP3 mRNA levels (B) evaluated by qRT-PCR at both 48 h and 72 h in NCI-H295R cells after livin transfection in comparison with those 
transfected with the empty vector (pCMV6). All qRT-PCR experiments were conducted in triplicates. (A) After 72 hours from transfection, 
the mRNA level of livin α and livin β were significantly increased in livin-NCI-H295R cells in comparison with those transfected with 
empty vector (p = 0.04 and p = 0.02 for livin α and livin β, respectively). (B) Livin overexpression was associated with a significant decrease 
of CASP3 mRNA levels after 72 hours from transfection (p = 0.015). (C) WB analysis showed clearly higher livin α and β protein levels 
and a light decrease of cleaved caspase 3 protein levels at both 48 and 72 hours. (D) Quantitative analysis of livin α, livin β and cleaved 
caspase-3 by WB in livin-NCI- H295R transfected cells in comparison with those transfected with the empty vector after 72 h. Livin α and 
livin β were significantly increased in livin-NCI-H295R cells in comparison with pCMV6-NCI-H295R (p = 0.0028 and p = 0.008 for livin 
α and livin β, respectively). Cleaved caspase-3 was only slightly decreased in livin-NCI- H295R transfected cells (p = n.s.). Each bar in 
the histograms represents the mean of the ratio between cleaved casp3 signal and α-tubulin signal. Each point represents the value of this 
ratio deriving from four separate experiments. (E) Immunofluorescence staining showed a decrease of cleaved caspase-3 protein levels 
(red color) in livin-NCI-H295R cells (green color) compared to pCMV6-NCI-H295R. Cell nuclei were visualized with 4#-6-diamidino-2-
phenylindole (DAPI, blue color). Magnification 60×. Statistical analysis by unpaired t-test with Welch’s correction. n.s.= p not significant.
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clinical outcome as observed in some [22, 27, 42], but not 
all other cancer types [20, 29, 44, 45]. Our results are in 
accordance to other recently published gene expression 
data in ACCs [39], where no significant relationship was 
observed between livin expression and overall survival 
(p = 0.86). This discrepancy compared to other human 
cancers may be at least partially due to the diverse 
antibodies and scoring system used in the previous studies, 
mostly including only small series of patients. In the 
present study, we used a highly specific antibody against 
the full-length recombinant human livin well suitable 
for immunohistochemistry and investigated a very large 
series of normal and neoplastic adrenocortical tissues. 
Furthermore, a major point to be considered is that livin 
does not regulate the apoptosis process alone, but it is part 
of a complex apparatus where several physio-pathological 
mechanisms are involved. Hence, in vitro experiment in the 
livin transfected ACC cell line NCI-H295R confirmed that 
livin overexpression was not able to induce cell proliferation 
or modifications in cell viability. This is also reflected by the 
fact that livin expression also did not correlate with survival 
in adrenocortical cancer. Additionally, in H295R cells, the 
livin overexpression induced a down-regulation of the 
expression of CASP3 at mRNA level. At the protein level, 
we evaluated the expression of cleaved caspase-3, which 
is a major effector of the intrinsic and extrinsic pathway of 
apoptosis, by IF analysis and WB. Although we observed 
in IF a significant reduction of the active caspase-3 in the 
evaluated cells, we did not obtain a significant decrease of 
cleaved caspase-3 at WB analysis. This difference could 
be related to the different sensitivity of the two methods, 
but we cannot exclude that livin overexpression produces 
only a slight decrease of the active form of caspase-3. 
Thus, we hypothesize that livin may be able to modulate 
apoptosis mainly via the partial inhibition of caspase-3 
also in adrenocortical cells, as previously reported in other 
cancer types [24, 30, 31]. So while livin does not lead to 
an increased malignity of the adrenocortical tumors, it 
might affect the cellular resistance to apoptosis, which 
may play an important role during treatment. However, 
not surprisingly, also additional mechanisms are likely to 
be involved in the complex mechanism of the apoptotic 
cascade in ACC. 
An open question is represented by the different 
distribution of the livin immunostaining between 
benign (preponderant positive nuclei) and malignant 
adrenocortical tumors (preponderant positive cytoplasm). 
As showed for other cancer types [19, 27, 40, 41, 45], we 
observed livin localized in both cytoplasm and nuclei. 
However, none of the previous observations described 
a significant difference in livin distribution between 
adenomas and carcinomas. Moreover, we report also a 
different distribution of livin staining among the three 
cortical zones and the medulla of the normal adrenal 
gland. The biological significance of these observations 
remains unclear [46]. To our knowledge, this is the first 
study which describes a difference in livin staining among 
normal tissue, benign and malignant tumors in a large 
series of adrenal tissues. As described in literature, livin 
is a regulator rather than an inhibitor of apoptosis and it 
could have both antiapoptotic or proapoptotic activity in 
the same tumor type based on protein levels [43] or cellular 
localization [46]. Nachmias and colleagues demonstrated 
that the full-length livin protein, which is associated with 
anti-apoptotic activity, is detected exclusively in the 
cytoplasm, whereas the accumulation of truncated livin in 
the nucleus is correlated with an increase in apoptosis [46]. 
The antibody we used for immunohistochemistry staining 
recognizes both the full-length and the truncated form 
of the livin protein. Thus, we are not able to distinguish 
between the anti-apoptotic, that could be associated 
with malignant tumors, and the pro-apoptotic livin form, 
which could be associated with benign tumors. However, 
we demonstrate that the ratio between cytoplasmic and 
nuclear staining was significantly higher in ACC than in 
ACA and NAG, while no significant difference was found 
between ACA and NAG. Here we may speculate that this 
different cell distribution of livin could be related with 
its pleiotropic activity in the regulation of the complex 
pathway of apoptosis that needs to be further investigated. 
Nevertheless, a different localization/distribution of 
livin inside the cells might be useful for the differential 
diagnosis between benign and malignant adrenocortical 
tumors, particularly when the lesion tends to be difficult to 
classify with classical histopathological methods, mostly 
based on Weiss score.
In terms of pathogenetic mechanisms, we observed 
a trend to a positive correlation between the livin protein 
levels and the BIRC7 copy number status. Specifically, 
the adrenocortical tumors with copy number gains in the 
chromosomal region including the BIRC7 gene showed 
a higher livin expression, thus suggesting a potential 
causative genomic alteration in this segment. 
We also observed a significant positive correlation 
between the livin and the survivin protein expression 
levels. The two IAPs are commonly overexpressed in 
several malignant tumors and both modulate apoptosis 
through the inhibition of caspases. Many studies indicated 
that survivin and livin play together an important role in 
tumorigenesis and are correlated with clinical outcome in 
human cancer [18, 47, 48]. However, in our series, only 
the survivin expression showed a significant negative 
impact on overall survival in patients with ACC, similarly 
to what was reported in previous studies in other cancer 
types [44, 45]. 
The high livin expression levels in malignant 
adrenocortical tumors also suggests that it might represent a 
novel potential drug target for patients with ACC [9, 49, 50]. 
Because IAP members block apoptosis at the down-stream 
effector phase, a point where multiple signaling pathways 
converge, they represent attractive molecular targets for 
the design of new classes of anticancer drugs aimed to 
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overcome apoptosis resistance of cancer cells [8, 16]. 
Several strategies to target livin in novel cancer therapies 
have been investigated, such as antisense nucleotides [51] 
and cancer immunotherapy [52]. However, it is worth 
noting that targeting livin might cause different side effects 
due to its known expression in several normal tissues 
(i.e. nephrotoxicity, gastrointestinal disorders, infertility, 
or adrenal disorder) [20, 22, 29, 40, 41]. While not strictly 
tumor-specific, the overexpression of livin in tumor cells 
represents a preferential rather than a specific cancer target 
that needs to be further investigated. This topic will be the 
object of future research projects. 
In conclusion, our findings demonstrate that livin 
is specifically over-expressed in ACC, suggesting that 
it might be involved in adrenocortical tumorigenesis 
and it might represent a possible new molecular marker 
of malignancy in adrenocortical tumors. Moreover, as 
previously reported for different human cancers, these 
findings might open a new perspective for the use of livin 
as a potential therapeutic target in ACC that deserves to be 
further investigated. 
MATERIALS AND METHODS
Tissue samples and clinical characteristic 
A total of 82 fresh-frozen adrenal tissues, collected 
between October 2006 and October 2014, were used 
for the evaluation of livin, its isoforms α and β, CASP3, 
XIAP and DIABLO mRNA levels. In particular, 
23 (NAG) deriving from the area surrounding the tumors 
(n = 20) or from adrenalectomies performed during 
surgery for renal carcinoma (n = 3) and 59 adrenocortical 
tumors (25 ACA and 34 ACC) have been investigated. 
Among these, 19 were paired samples of tumors and 
corresponding adjacent normal adrenal glands (13 ACA 
and 6 ACC). In a subgroup of 15 out of 19 paired samples 
with enough material (10 ACA and 5 ACC), livin protein 
expression was also investigated by WB analysis. Among 
the ACC group, 29 tissues were primary tumors, 1 local 
recurrence and 4 distant metastases. The last follow-up 
was January 2016. Patients undergone adrenalectomy for 
primary tumor presented a median follow-up of 31 months 
(range 3–189 months). Among these, 13 were died for the 
disease, 15 were still alive at the last follow-up and 1 was 
lost from the follow-up.
For the livin immunohistochemistry analysis, 
we investigated 314 paraffin-embedded tissue sections 
(including 192 ACC, 58 ACA, 20 NAG, 6 other normal 
tissues, 38 other cancers), comprising 171 standard full 
slides and 143 assembled in three tissue microarrays 
(TMA). TMA were assembled as previously reported [53] 
and only patients with at least 2 out of 5 evaluable cores 
in the TMA after the staining procedure were included 
in the final series. A total of 250 adrenocortical tumor 
samples were evaluated. These adrenocortical tumor 
tissues included 32 samples (17 ACA and 15 ACC) that 
had been investigated in a previous SNP array analysis 
[35] and which were used for the comparison between 
copy number alteration and protein expression. Among 
the ACC group, 147 tissues were primary tumors, 25 local 
recurrences and 20 distant metastases. The last follow-up 
was January 2016. Patient underwent to adrenalectomy for 
primary tumor presented a median follow-up of 37 months 
(range 1–224 months). Among these, 86 were died for the 
disease, 57 were still alive at the last follow-up and 4 were 
lost from the follow-up.
For the comparison between livin protein staining 
and mRNA levels, we evaluated a total of 31 tissue samples, 
including 10 ACA and 21 ACC. We also investigated other 
non-adrenal tissues, comprising 6 normal tissues (liver, 
ovary, uterus, stomach and 2 samples of tonsils) and 
38 tissues from several cancers (melanoma, lymphoma, 
renal cell carcinoma, bladder cancer, colon cancer, 
hepatocellular cancer, pancreatic cancer, breast cancer, 
ovarian cancer, testicular cancer, prostatic cancer, bronchial 
cancer and non-small cell lung cancer) as controls. 
Clinical parameters, such as sex, age at diagnosis, 
tumor size, hormone secretion pattern, pathological 
classification and, in case of ACC, tumor stage according 
to the European Network for the Study of Adrenal 
Tumors (ENSAT) classification [54], Weiss score, Ki67 
proliferation index, presence and number of distant 
metastasis, clinical outcome were collected through the 
German ACC and the ENSAT Registry (www.ensat.org). 
Hormonal hypersecretion and malignancy of the tumors 
were defined according to established clinical, biochemical 
and pathological criteria [5, 55]. Clinical parameters and 
tumor characteristics are summarized in Table 1.  
The study was approved by the ethics committee of 
the University of Wuerzburg (No. 93/02 and 88/11) and 
written informed consent was obtained from all patients.
Cancer cell lines 
The livin/BIRC7 expression was also investigated 
in three different ACC cell lines: the reference NCI-H295 
cell line and the adherent variant NCI-H295R (both 
steroid-secreting) as well as SW13, a non-steroid secreting 
cell line. NCI-H295 and NCI-H295R were cultured as 
previously described [56, 57]. SW13 were cultured in L15 
Leibowitz medium with 10% FCS and 1% L-glutamine. 
STR profiling confirmation was performed on all the 
cell lines. Mycoplasma contamination PCR tests have 
been performed regularly and cells were maintained 
mycoplasma-free. 
For the livin isoforms expression in ACC cell lines, 
two human neuroblastoma cell lines (IMR32 and SKN-MC) 
and Hela cells were used as positive controls, as previously 
reported [13, 22]. These three cell lines were cultured as 
previously described in DMEM-AQ medium with 10% 
FCS [57].
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Table 1: Clinical and pathological characteristics of both cohorts of patients for (A) mRNA and 
(B) protein analysis
A. Cohort of patients for mRNA analysis by qRT-PCR
ACA ACC p value
n 25 34 n.s.
Sex (F:M) 16:9 18:16 n.s.
Age yrs-median (range) 49.5 (25–69) 50 (22–80) n.s.
Tumor size cm-median (range) 3.2 (0.9–6.5) 7.6 (2.5–24.0) < 0.05
Hormone secretion - n available
Cortisol – n (%)
Androgen – n (%)
Aldosterone – n (%)
Inactive – n (%)
25
11 (44%)
0 (0%)
7 (28%)
7 (28%)
34
15 (44%)
4 (12%)
1 (3%)
14 (41%)
n.s.
Tumor localization
Primary tumor 
Local recurrences Metastases
– 291
4
n.a.
ENSAT Tumor Stage-n available
I–II – n (%)
III – n (%)
IV – n (%)
–
32
13 (41%)
11 (34%)
8 (25%)
n.a.
Ki67 index - median (range) – 20 (2–70) n.a.
Weiss score - median (range) – 7 (2–9) n.a.
B. Cohort of patients for protein analysis by immunohistochemistry
ACA ACC p value
n tissues 58 192 
n patients 58 166 n.s.
Sex (F:M) 41:17 99:66 n.s.
Age yrs-median (range) 52.5 (2–76) 46 (7–80) n.s.
Tumor size cm-median (range) 3.75 (1.5–14) 11  (3–30) < 0.05
Hormone secretion-n available
Cortisol – n (%)
Androgen – n (%)
Aldosterone – n (%)
Mixed – n (%)
Inactive – n (%)
58
20 (34.5%)
0 (0 %)
13 (22.4%)
0 (0%)
25 (43.1%)
115
43 (37.5%)
19 (16.5%)
5 (4.3%)
26 (22.6%)
22 (19.1%)
n.s.
Tumor localization
Primary tumor – n
Local recurrences – n
Metastases – n
– 14725
20
n.a.
ENSAT Tumor Stage-n available
I–II – n (%)
III – n (%)
IV – n (%)
–
159
80 (50.3%)
46 (28.9%)
33 (20.8%)
n.a.
Ki67 index-median  (range) – 10 (1–80) n.a.
Weiss score-median (range) – 5 (2–9) n.a.
Abbreviation: ACA: adrenocortical adenoma; ACC: adrenocortical carcinoma; n: number; F: female; M: male; yrs: years; 
n.a.: data not applicable; n.s.: p not significant. 
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All cell lines were available in our laboratory 
and have been reauthenticated using STR-Analysis on 
February 2016 in the Department of Clinical Chemistry 
and Laboratory Medicine, University Hospital Würzburg.
Quantitative real-time reverse transcription 
PCR 
Livin, its isoforms α and β, CASP3, XIAP and 
DIABLO mRNA expression levels were analyzed by 
quantitative real-time PCR (qRT-PCR). In brief, RNA 
was isolated from fresh frozen tissue samples using 
the RNeasy Lipid Tissue Minikit (Qiagen, Hilden, 
Germany) and from cells using the RNeasy Mini Kit 
(Qiuagen). Reverse transcription of 1 µg of RNA was 
performed using the QuantiTect Reverse Transcription Kit 
(Qiagen) according to manufacturer’s recommendations. 
Predesigned Taqman® gene expression assays for livin 
(Hs01086675_m1), CASP3 (Hs00234387_m1), XIAP 
(Hs00745222_s1) and DIABLO (Hs00219876_m1) 
(Applied Biosystems, Darmstadt, Germany) were used. 
For livin α and β isoforms we designed the amplification 
primer and the TaqMan hybridization probes spanning the 
5′-part of exon 6 for livin β (Supplementary Table S2A). 
Beta actin (Hs9999903_m1) expression was used for 
normalization. For each PCR reaction 40 ng cDNA were 
used as template and each reaction was performed in 
duplicate. Amplification was performed using the TaqMan 
Gene Expression Master Mix (Applied Biosystems) and 
the CFX96 real-time thermocycler (Bio-Rad, California, 
USA). Cycling conditions were: 95°C for three min 
followed by 50 cycles of 95°C for 30 sec, 60°C for 30 sec, 
and 72°C for 30 sec. Transcript levels were determined 
using Bio-Rad CFX Manager 2.0 software and normalized 
to those of housekeeping gene using the ∆CT method 
(Pfaffl), as previously described [58]. 
Reverse transcription-PCR
To compare the expression of the livin isoforms α 
and β in ACT and in adjacent NAG and in ACC cell lines, 
we additionally performed regular RT-PCR followed by 
size differentiation agarose electrophoresis. The primers 
used amplify a fragment including the 5′-part of exon 6, 
deleted in livin β [22] (Supplementary Table 2B). The 
expression of endogenous β2-microglobulin [18] was used 
for normalization. Primers were purchased from Eurofins 
Genomics (Ebersberg, Germany). RT-PCR was performed 
using the Sybr Green PCR Master Mix (Life Technologies, 
Warrington, UK). PCR products were identified by 4% 
agarose gel electrophoresis. We differentiated between 
two fragment sizes: 216 bp band for livin α and 162 bp 
for livin β. After gel documentation (Biometra, Göttingen, 
Germany) a semi-quantitative evaluation of the bands was 
performed using the Image Studio software 4.0 (LI-COR, 
Bad Homburg, Germany). Hela cells were used as positive 
control [13].
Western blot analysis
For both WB and immunostaining analysis, we 
selected a rabbit polyclonal antibody (Ab) raised against 
livin (NB100-56145, Novus Biologicals, Hamburg, 
Germany, 1:1000), for which a synthetic peptide 
corresponding to amino acids 180–230 of human livin was 
used as immunogen (full-length recombinant human livin). 
For the WB analysis, proteins were extracted from 
fresh-frozen tissues and cells as previously described 
[56, 59]. Tissues samples were homogenized by sonication 
at 4°C in RIPA buffer (Sigma-Aldrich, Missouri, USA) 
supplemented with Protease Inhibitor Cocktail (Sigma-
Aldrich). Whole cell lysate SK-MEL 28 (sc-2236, 
Santa Cruz Biotechnology Inc., Heidelberg, Germany), 
derived from the melanoma CSK-MEL-28 cell line, was 
used as positive control for WB [60]. Electrophoresis 
of equal amounts of proteins was performed in a 12% 
SDS-polyacrylamide gel and transferred onto a PVDF 
membrane by tank-blotting. The membrane was blocked 
with 5% skim milk in TBS-Tween and incubated overnight 
at 4°C with the primary Ab against livin (dilution 
1:1000). After washing, the membrane was incubated 
with horseradish peroxidase-labeled goat anti-rabbit IgG 
(NA934-100UL, Ge Healthcare, Little Chalfont, United 
Kingdom, 1:5000). The antigen-antibody complex was 
visualized by enhanced chemiluminescence using an 
Amerscham ECL reagent (WesternSure PREMIUM 
Chemiluminescent Substrate, LI-COR). Normalization 
of protein levels was performed by re-probing the blot 
with the antibody recognizing human β-actin (Sigma-
Aldrich, 1:5000). A scan of the membrane was performed 
by C-DiGit Blot Scanner (LI-COR) and the quantification 
of individual bands was measured using the Image Studio 
software 4.0 (LI-COR). Two specific bands of 39 and 
37 kDa corresponding to livin α and livin β, respectively, 
were detected in both positive control and adrenal tissues.
Immunohistochemistry
Full serial sections and TMA were deparaffinized 
with xylol and rehydrated in descending graded series of 
ethanol. Immunohistochemical detection was performed 
with an indirect immunoperoxidase technique after 
high temperature antigen retrieval in 10 mM citric 
acid monohydrate buffer (pH 6.5) in a pressure cooker 
for 13 min. Blocking of unspecific protein–antibody 
interactions was performed with 20% human AB serum in 
PBS for 1 hour at room temperature. Tissue sections were 
incubated at room temperature for 1 hour with the primary 
polyclonal rabbit anti-livin Ab (NB100-56145, Novus 
Biologicals, 1:1000). As negative control, tissue sections 
were incubated with N-Universal Negative Control Anti-
Rabbit (Dako, Glostrup, Denmark). Signal amplification 
was achieved at room temperature by En-Vision System 
Labeled Polymer-HRP Anti-Rabbit (Dako) for 40 min 
followed by 10 min development with DAB Substrate Kit 
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(Vector Laboratories, California, USA) according to the 
manufacturer’s instructions. Nuclei were counterstained 
with Mayer’s hematoxylin for 2 min. As positive control, 
tissue sections from melanoma and renal clear cells 
carcinoma were stained. 
All slides were analyzed independently by two 
investigators blinded to clinical information (B.A. and 
S.St.). Cytoplasmic livin staining was evaluated in all 
tissue samples measuring the staining intensity and the 
percentage of positive cells. The staining intensity was 
graded as negative (0), low (1), medium (2), or strong (3). 
The percentage of positive cells was scored as 0 if 0% were 
positive, as 0.1 if 1–9% were positive, as 0.5 if 10–49% 
were positive, and as 1 if 50% or more were positive. A 
semiquantitative H-score for the cytoplasmic localization 
was then calculated multiplying the staining intensity 
grading score by the proportion score as described 
previously [61]. Nuclear staining of livin was also evaluated 
in the group of adrenocortical tissues and the percentage 
of positive nuclei was scored as 1 if 0%, as 2 if 1–49%, 
and as 3 if 50% or more were stained. When discrepancies 
were observed, results were jointly assessed by both 
investigators and the final score was decided by consensus. 
Inter-observer agreement was strong, with a Spearman’s 
correlation coefficient of 0.87 (95% CI 0.84–0.90).
All images were acquired by light microscopy 
(Biorevo BZ-9000, Keyence) using same light intensity 
parameters to avoid biased information. Original images 
were used for the analysis; printed images were modified 
in brightness and contrast. 
Relationship between livin and survivin 
immunostaining
We took advantage from the data already available 
in our institute about survivin/BIRC5 protein expression 
in a large series of adrenal samples [36]. Thus, we could 
investigate the relationship between livin and survivin 
cytoplasmatic immunostaining, and their potential 
synergistic role on clinical outcome, in a subgroup of 146 
adrenal samples (118 ACC, 20 ACA and 8 NAG) where 
data were available for both proteins.
In vitro experiments
NCI-H295R cells were cultured as previously 
described and grown as monolayers in DMEM/
F12 (1:1) medium (Gibco, Invitrogen Ltd., UK) 
supplemented with 5 ml of insulin, transferrin 
and selenium solution (IST, Gibco, 41400-045) 
and 2.5% Nu-serum (Corning, Thermo Fisher Scientific, 
Manasses, VA, USA) at 37°C and 5% CO2 [56, 57]. One 
day prior to transfection , 6 × 10^5 cells were seeded in 
6 well plates. 2 µg of vector DNA were diluted in 200 
µl OPTI-MEM serum-free media (Gibco) and 6 µl of the 
X-treme GENE HP DNA transfection reagent (Sigma 
Aldrich) was added and incubated 20 min at room 
temperature. Transient livin overexpression was induced 
in the ACC cell line NCI-H295R by using a TrueORF 
Gold Myc-DDK-tagged livin cDNA clone (RC204906, 
OriGene, Herford, Germany). An empty pCMV6-Entry 
vector was used as control. The livin transfection rate 
was confirmed by qRT-PCR and WB and all experiments 
were conducted at least in triplicates. As a marker of 
apoptosis, we evaluated the CASP3 expression by qRT-
PCR and the cleaved caspase-3 by both WB and IF. qRT-
PCR for livin α, livin β and CASP 3 was performed as 
earlier described. For WB analysis, the protein lysates 
were blotted onto nitrocellulose membranes and incubated 
with livin antibody (1:1000), cleaved caspase-3 antibody 
(#9661, Cell Signaling, 1:250) and α-tubulin antibody for 
the normalization of protein levels (clone DM1A, T9026, 
Sigma-Aldrich, 1:40000). Because we observed significant 
results after 72 hours, we decide to proceed with IF at this 
time point. For IF, cells were grown in chamberslides 
and transfected as described. After 72 h hours, cells were 
subsequently fixed in 4% paraformaldehyde in PBS for 
8 min, washed with PBS and permealised with 0.5% 
Triton X100 in PBS for five minutes. After washing, 
cell were incubated overnight at 4°C with mouse anti-
FLAG antibody (clone M2, F1804, Sigma-Aldrich, 1:50) 
and rabbit anti-cleaved caspase 3 antibody (1:50). For 
detection, cells were incubated with Alexa Fluor-488 or 
-594 (Molecular Probes, Invitrogen) labeled anti-mouse 
or anti-rabbit secondary antibodies, respectively, at room 
temperature for one hour. Cells were mounted with 
Vectashield antifade mounting medium containing DAPI 
(H-1200, Vector Laboratories, Burlingame, CA, USA). 
Image acquisition was performed using a flourescence 
microscope (Axiovert 135, Carl Zeiss). Merged images 
were obtained using the corresponding software 
(AxioVision, Carl Zeiss). Cell from three separate 
experiments were counted automatically with ImageJ 
software, for a total count of more than 1000 cells. 
A cell viability test using the WST-1 proliferation 
reagent was performed according to the manufacturer’s 
protocol (Roche Diagnostics Deutschland GmbH, 
Mannheim, Germany) at both 48 and 72 hours after the 
transfection. After adding WST-1 reagent, absorbance 
was measured using a microplate reader (1420 VICTOR3, 
PerkinElmer Inc., Waltham, MA, USA) after two hours. At 
least six wells were used for each experimental condition 
and all experiments were conducted in triplicates.
Statistical analysis
The Fisher’s exact test or the Chi-square test was 
used to investigate dichotomic variables, while a two-
sided t test (or non-parametric test) was used to test 
continuous variables as appropriate. A non-parametric 
Kruskal-Wallis test, followed by Bonferroni post-hoc 
test, was used for comparison among several groups for 
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non-normal distributed variables. Correlations and 95% 
confidence intervals (95%CI) between different parameters 
were evaluated by linear regression analysis. Overall 
survival (OS) was defined as the time from the date of 
primary surgery to disease-related death or last follow-
up. Progression-free survival (PFS) was defined as the 
time from the date of complete tumor resection to the first 
radiological evidence of disease relapse or disease-related 
death. All survival curves were obtained by Kaplan-Meier 
estimates and the differences between survival curves were 
assessed by the log-rank (Mantel-Cox) test. In this context, 
the RNA expression was considered both as a categorical 
value (cut-off for this data set: median +2SD) and as 
an ordinal variable (high, medium and low expression: 
< 25%, 25–75%, and > 75% percentile, respectively). A 
multivariate regression analysis was performed by Cox 
proportional hazard regression model to identify those 
factors that might independently influence survival. 
Statistical analyses were made using GraphPad Prism 
(version 5.0, La Jolla, CA, USA) and SPSS Software 
(PASW Version 21.0, SPSS Inc., Chicago, IL, USA). 
P values < 0.05 were considered as statistically significant. 
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